Physician profile
Cheng Chen
NPI 1396803474
$9,799.89
in general payments reported to CMS, 2019-2025
20 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,446 · 2020: $926 · 2021: $795 · 2022: $678 · 2023: $965 · 2024: $2,010 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Travel and Lodging: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.93 |
| Travel and Lodging | $224.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,670.00 | 2019-2025 | Livdelzi, Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $2,486.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $675.36 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $577.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $470.74 | 2024-2025 | |
| Novo Nordisk INC | $440.62 | 2019-2020 | |
| Astrazeneca Uk Limited | $420.24 | 2024 | |
| Madrigal Pharmaceuticals | $392.05 | 2024-2025 | Rezdiffra |
| Amarin Pharma, INC. | $261.90 | 2019 | |
| Edwards Lifesciences Corporation | $241.75 | 2019 | |
| Abiomed | $180.51 | 2025 | |
| Glaxosmithkline, LLC. | $150.89 | 2023-2024 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Abbott Laboratories | $146.75 | 2025 | Proclaim |
| Ipsen Biopharmaceuticals, INC | $139.79 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.67 | 2023-2025 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $123.63 | 2025 | Mako, Flowtriever |
| Shionogi INC | $100.05 | 2019 | |
| Allergan, INC. | $92.85 | 2020 | |
| Horizon Therapeutics Plc | $76.56 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $16.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.